BioNexus Cost Of Revenue vs Current Deferred Revenue Analysis

BGLC Stock

USD 0.40 0.02 5.26%

BioNexus Gene financial indicator trend analysis is way more than just evaluating BioNexus Gene Lab prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioNexus Gene Lab is a good investment. Please check the relationship between BioNexus Gene Cost Of Revenue and its Current Deferred Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNexus Gene Lab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Cost Of Revenue vs Current Deferred Revenue

Cost Of Revenue vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioNexus Gene Lab Cost Of Revenue account and Current Deferred Revenue. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between BioNexus Gene's Cost Of Revenue and Current Deferred Revenue is -0.67. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of BioNexus Gene Lab, assuming nothing else is changed. The correlation between historical values of BioNexus Gene's Cost Of Revenue and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of BioNexus Gene Lab are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Cost Of Revenue i.e., BioNexus Gene's Cost Of Revenue and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

-0.67

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Cost Of Revenue

Cost of Revenue is found on BioNexus Gene Lab income statement and represents the costs associated with goods and services BioNexus Gene provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from BioNexus Gene's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioNexus Gene Lab current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNexus Gene Lab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

At present, BioNexus Gene's Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 0.87, whereas Tax Provision is forecasted to decline to about 114.1 K.

	2022	2023	2024	2025 (projected)
Gross Profit	1.3M	1.3M	1.5M	1.2M
Total Revenue	10.9M	9.8M	11.2M	8.4M

Gross Profit Total Revenue

BioNexus Gene fundamental ratios Correlations

	Total Current Liabilities	Net Tangible Assets	Retained Earnings	Other Stockholder Equity	Total Current Assets	Common Stock	Other Current Liab	Other Liab	Accounts Payable	Net Receivables	Inventory	Property Plant Equipment	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Total Liab	Net Invested Capital	Long Term Investments
Total Current Liabilities		0.85	0.11	-0.71	0.87	0.73	-0.66	0.57	0.54	0.91	0.9	0.91	0.87	0.45	0.81	0.92	-0.59	0.53	0.8	0.53	0.71	0.47	0.45	0.96	0.81	0.58
Net Tangible Assets	0.85		-0.2	-0.72	0.99	0.94	-0.8	0.87	0.59	0.77	0.94	0.93	0.95	0.53	0.93	0.96	-0.83	0.81	0.94	0.81	0.91	0.65	0.53	0.91	0.93	0.89
Retained Earnings	0.11	-0.2		0.1	-0.28	-0.47	0.06	-0.33	0.03	0.41	-0.02	-0.04	-0.22	-0.69	-0.3	-0.1	0.68	-0.71	-0.28	-0.71	-0.29	-0.68	-0.69	0.08	-0.3	-0.55
Other Stockholder Equity	-0.71	-0.72	0.1		-0.72	-0.8	0.88	-0.53	-0.81	-0.55	-0.64	-0.66	-0.63	-0.35	-0.61	-0.66	0.5	-0.47	-0.63	-0.47	-0.63	-0.35	-0.35	-0.64	-0.61	-0.55
Total Current Assets	0.87	0.99	-0.28	-0.72		0.95	-0.76	0.84	0.57	0.74	0.93	0.92	0.95	0.62	0.93	0.96	-0.87	0.85	0.93	0.85	0.89	0.7	0.62	0.91	0.93	0.89
Common Stock	0.73	0.94	-0.47	-0.8	0.95		-0.79	0.84	0.61	0.54	0.81	0.81	0.87	0.65	0.88	0.85	-0.89	0.9	0.88	0.9	0.87	0.73	0.65	0.75	0.88	0.92
Other Current Liab	-0.66	-0.8	0.06	0.88	-0.76	-0.79		-0.57	-0.94	-0.63	-0.71	-0.73	-0.69	-0.37	-0.66	-0.73	0.51	-0.49	-0.68	-0.49	-0.68	-0.35	-0.37	-0.71	-0.66	-0.58
Other Liab	0.57	0.87	-0.33	-0.53	0.84	0.84	-0.57		0.27	0.49	0.79	0.75	0.81	0.37	0.84	0.78	-0.81	0.82	0.87	0.82	0.92	0.65	0.37	0.63	0.84	0.95
Accounts Payable	0.54	0.59	0.03	-0.81	0.57	0.61	-0.94	0.27		0.54	0.5	0.54	0.48	0.29	0.42	0.53	-0.29	0.28	0.43	0.28	0.42	0.15	0.29	0.58	0.42	0.32
Net Receivables	0.91	0.77	0.41	-0.55	0.74	0.54	-0.63	0.49	0.54		0.83	0.81	0.73	0.15	0.64	0.82	-0.36	0.32	0.65	0.32	0.57	0.17	0.15	0.93	0.64	0.43
Inventory	0.9	0.94	-0.02	-0.64	0.93	0.81	-0.71	0.79	0.5	0.83		0.98	0.97	0.52	0.94	0.98	-0.73	0.67	0.94	0.67	0.9	0.63	0.52	0.94	0.94	0.76
Property Plant Equipment	0.91	0.93	-0.04	-0.66	0.92	0.81	-0.73	0.75	0.54	0.81	0.98		0.98	0.56	0.96	0.99	-0.73	0.66	0.96	0.66	0.9	0.67	0.56	0.94	0.96	0.75
Total Assets	0.87	0.95	-0.22	-0.63	0.95	0.87	-0.69	0.81	0.48	0.73	0.97	0.98		0.66	0.99	0.99	-0.84	0.79	0.99	0.79	0.93	0.78	0.66	0.91	0.99	0.84
Short Long Term Debt Total	0.45	0.53	-0.69	-0.35	0.62	0.65	-0.37	0.37	0.29	0.15	0.52	0.56	0.66		0.69	0.58	-0.79	0.77	0.64	0.77	0.55	0.88	1.0	0.49	0.69	0.59
Total Stockholder Equity	0.81	0.93	-0.3	-0.61	0.93	0.88	-0.66	0.84	0.42	0.64	0.94	0.96	0.99	0.69		0.96	-0.88	0.82	0.99	0.82	0.96	0.84	0.69	0.85	1.0	0.88
Property Plant And Equipment Net	0.92	0.96	-0.1	-0.66	0.96	0.85	-0.73	0.78	0.53	0.82	0.98	0.99	0.99	0.58	0.96		-0.78	0.73	0.96	0.73	0.9	0.68	0.58	0.96	0.96	0.8
Net Debt	-0.59	-0.83	0.68	0.5	-0.87	-0.89	0.51	-0.81	-0.29	-0.36	-0.73	-0.73	-0.84	-0.79	-0.88	-0.78		-0.98	-0.86	-0.98	-0.83	-0.89	-0.79	-0.64	-0.88	-0.94
Cash	0.53	0.81	-0.71	-0.47	0.85	0.9	-0.49	0.82	0.28	0.32	0.67	0.66	0.79	0.77	0.82	0.73	-0.98		0.81	1.0	0.79	0.86	0.77	0.6	0.82	0.95
Non Current Assets Total	0.8	0.94	-0.28	-0.63	0.93	0.88	-0.68	0.87	0.43	0.65	0.94	0.96	0.99	0.64	0.99	0.96	-0.86	0.81		0.81	0.97	0.81	0.64	0.84	0.99	0.89
Cash And Short Term Investments	0.53	0.81	-0.71	-0.47	0.85	0.9	-0.49	0.82	0.28	0.32	0.67	0.66	0.79	0.77	0.82	0.73	-0.98	1.0	0.81		0.79	0.86	0.77	0.6	0.82	0.95
Common Stock Shares Outstanding	0.71	0.91	-0.29	-0.63	0.89	0.87	-0.68	0.92	0.42	0.57	0.9	0.9	0.93	0.55	0.96	0.9	-0.83	0.79	0.97	0.79		0.76	0.55	0.75	0.96	0.91
Non Current Liabilities Total	0.47	0.65	-0.68	-0.35	0.7	0.73	-0.35	0.65	0.15	0.17	0.63	0.67	0.78	0.88	0.84	0.68	-0.89	0.86	0.81	0.86	0.76		0.88	0.5	0.84	0.79
Capital Lease Obligations	0.45	0.53	-0.69	-0.35	0.62	0.65	-0.37	0.37	0.29	0.15	0.52	0.56	0.66	1.0	0.69	0.58	-0.79	0.77	0.64	0.77	0.55	0.88		0.49	0.69	0.59
Total Liab	0.96	0.91	0.08	-0.64	0.91	0.75	-0.71	0.63	0.58	0.93	0.94	0.94	0.91	0.49	0.85	0.96	-0.64	0.6	0.84	0.6	0.75	0.5	0.49		0.85	0.65
Net Invested Capital	0.81	0.93	-0.3	-0.61	0.93	0.88	-0.66	0.84	0.42	0.64	0.94	0.96	0.99	0.69	1.0	0.96	-0.88	0.82	0.99	0.82	0.96	0.84	0.69	0.85		0.88
Long Term Investments	0.58	0.89	-0.55	-0.55	0.89	0.92	-0.58	0.95	0.32	0.43	0.76	0.75	0.84	0.59	0.88	0.8	-0.94	0.95	0.89	0.95	0.91	0.79	0.59	0.65	0.88

Click cells to compare fundamentals

BioNexus Gene Account Relationship Matchups

BioNexus Gene fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Current Liabilities	3.4M	2.3M	2.0M	1.6M	1.9M	1.5M
Net Tangible Assets	1.5M	1.1M	6.7M	7.2M	8.3M	8.7M
Retained Earnings	760.8K	1.5M	1.2M	(1.8M)	(1.7M)	(1.6M)
Total Current Assets	8.0M	7.1M	6.0M	8.0M	9.3M	9.7M
Other Current Liab	50.1K	32.3K	103.4K	194.1K	174.7K	169.0K
Net Receivables	4.0M	3.4M	2.9M	857.3K	985.9K	1.8M
Inventory	1.2M	1.5M	977.8K	1.1M	1.3M	765.1K
Property Plant Equipment	341.8K	336.5K	1.8M	1.6M	1.9M	961.7K
Total Assets	10.1M	9.6M	8.7M	11.4M	13.1M	7.8M
Short Long Term Debt Total	123.4K	76.9K	56.8K	133.4K	153.4K	103.0K
Total Stockholder Equity	6.7M	7.2M	6.7M	9.7M	11.1M	6.0M
Property Plant And Equipment Net	1.8M	1.7M	1.6M	1.7M	1.9M	1.4M
Net Debt	(2.7M)	(2.0M)	(2.1M)	(5.8M)	(5.2M)	(5.0M)
Cash	2.8M	2.1M	2.1M	5.9M	6.8M	7.2M
Non Current Assets Total	2.1M	2.4M	2.7M	3.4M	3.9M	2.1M
Cash And Short Term Investments	2.8M	2.1M	2.1M	5.9M	6.8M	7.2M
Common Stock Shares Outstanding	8.6M	14.3M	14.4M	15.9M	18.3M	12.1M
Liabilities And Stockholders Equity	10.1M	9.6M	8.7M	11.4M	13.1M	7.8M
Non Current Liabilities Total	79.5K	65.9K	71.1K	111.0K	127.7K	82.9K
Capital Lease Obligations	123.4K	76.9K	56.8K	133.4K	153.4K	103.0K
Total Liab	3.5M	2.4M	2.1M	1.7M	2.0M	1.8M
Net Invested Capital	6.7M	7.2M	6.7M	9.7M	11.1M	6.0M
Long Term Investments	281.7K	749.0K	1.2M	1.7M	2.0M	2.1M
Accumulated Other Comprehensive Income	133.7K	(100.3K)	(409.1K)	(677.3K)	(609.6K)	(579.1K)
Net Working Capital	4.6M	4.8M	4.0M	6.4M	7.4M	4.0M
Short Term Debt	91.5K	79.0K	16.6K	34.6K	39.8K	50.0K
Other Current Assets	6.1M	147.1K	1.5M	122.4K	110.2K	104.7K
Property Plant And Equipment Gross	1.8M	1.6M	2.2M	2.3M	2.7M	1.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GM	General Motors
C	Citigroup

When determining whether BioNexus Gene Lab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNexus Gene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionexus Gene Lab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionexus Gene Lab Stock:

How To Invest In BioNexus

Details

Is BioNexus Stock a good investment?

Details

What is BioNexus Gene's Net Worth?

Details

Largest Specialty Chemicals Companies

View

Largest Basic Materials Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNexus Gene Lab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Is Specialty Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNexus Gene. If investors know BioNexus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNexus Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.95)

Earnings Share

(0.06)

Revenue Per Share

0.526

Quarterly Revenue Growth

(0.23)

Return On Assets

(0.10)

The market value of BioNexus Gene Lab is measured differently than its book value, which is the value of BioNexus that is recorded on the company's balance sheet. Investors also form their own opinion of BioNexus Gene's value that differs from its market value or its book value, called intrinsic value, which is BioNexus Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNexus Gene's market value can be influenced by many factors that don't directly affect BioNexus Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between BioNexus Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNexus Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNexus Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BioNexus Cost Of Revenue vs Current Deferred Revenue Analysis

Cost Of Revenue vs Current Deferred Revenue

Cost Of Revenue vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Current Deferred Revenue

BioNexus Gene fundamental ratios Correlations

BioNexus Gene Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioNexus Gene fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Capital Lease Obligations	+ 1.0	Short Long Term Debt Total
Net Invested Capital	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 0.99	Net Tangible Assets
Property Plant And Equipment Net	+ 0.99	Property Plant Equipment
Total Stockholder Equity	+ 0.99	Total Assets

Cash And Short Term Investments	- 0.98	Net Debt
Cash	- 0.98	Net Debt
Long Term Investments	- 0.94	Net Debt
Accounts Payable	- 0.94	Other Current Liab
Non Current Liabilities Total	- 0.89	Net Debt
Net Debt	- 0.89	Common Stock